European Society of Gastrointestinal Endoscopy (ESGE)Guideline: Prophylaxis of post-ERCP pancreatitis

Endoscopy

Volumn 42, Issue 6, 2010, Pages 503-515

  Dumonceau, J M ^a   Andriulli, A ^b   Deviere, J ^c   Mariani, A ^d   Rigaux, J ^c   Baron, T H ^e   Testoni, P A ^d  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c ERASME HOSPITAL   (Belgium)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLCYSTEINE; ADRENALIN; ALLOPURINOL; AMYLASE; BETA CAROTENE; BOTULINUM TOXIN; CEFTAZIDIME; CONTRAST MEDIUM; DICLOFENAC; GABEXATE; GLUCOCORTICOID; GLYCERYL TRINITRATE; HEPARIN; INDOMETACIN; INTERLEUKIN 10; LIDOCAINE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PENTOXIFYLLINE; PLACEBO; SEMAPIMOD; SOMATOSTATIN; ULINASTATIN;

ABSENCE OF SIDE EFFECTS; AMYLASE BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SPHINCTEROTOMY; GASTROINTESTINAL ENDOSCOPY; GUIDE WIRE; HEADACHE; HUMAN; HYPOTENSION; LOW DRUG DOSE; MANOMETRY; MEDICAL SOCIETY; ODDI SPHINCTER; PANCREATITIS; PATIENT POSITIONING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT FAILURE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATHETERIZATION; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; GASTROINTESTINAL AGENTS; HUMANS; PANCREATITIS; PROSTHESIS IMPLANTATION; RISK FACTORS; STENTS;

EID: 77952971437     PISSN: 0013726X     EISSN: 14388812     Source Type: Journal    
DOI: 10.1055/s-0029-1244208     Document Type: Review

References (137)

1. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001 323 334-336
2. Freeman M L., Nelson D B., Sherman S et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996 335 909-918
3. Choi C W., Kang D H., Kim G H. et al. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. Gastrointest Endosc 2009 69 e11-e18
4. Lee K T., Lee D H., Yoo B M. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas 2008 37 445-448
5. Cotton P B., Lehman G, Vennes J et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991 37 383-393
6. Bradley E L. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, GA, September 11 through 13, 1992: Arch Surg 1993 128 586-590
7. Testoni P A., Caporuscio S, Bagnolo F, Lella F. Twenty-four-hour serum amylase predicting pancreatic reaction after endoscopic sphincterotomy. Endoscopy 1999 31 131-136
8. Bretthauer M, Seip B, Aasen S et al. Carbon dioxide insufflation for more comfortable endoscopic retrograde cholangiopancreatography: a randomized, controlled, double-blind trial. Endoscopy 2007 39 58-64
9. Andriulli A, Loperfido S, Napolitano G et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007 102 1781-1788
10. Masci E, Mariani A, Curioni S, Testoni P A. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy 2003 35 830-834
11. Freeman M L., DiSario J A., Nelson D B. et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001 54 425-434
12. Loperfido S, Angelini G, Benedetti G et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998 48 1-10
13. Masci E, Toti G, Mariani A et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001 96 417-423
14. Williams E J., Taylor S, Fairclough P et al. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endoscopy 2007 39 793-801
15. Harewood G C., Pochron N L., Gostout C J. Prospective, randomized, controlled trial of prophylactic pancreatic stent placement for endoscopic snare excision of the duodenal ampulla. Gastrointest Endosc 2005 62 367-370
16. Norton I D., Gostout C J., Baron T H. et al. Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc 2002 56 239-243
17. Fazel A, Quadri A, Catalano M F., Meyerson S M., Geenen J E. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc 2003 57 291-294
18. Smithline A, Silverman W, Rogers D et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 1993 39 652-657
19. Tarnasky P R., Palesch Y Y., Cunningham J T. et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998 115 1518-1524
20. Andriulli A, Forlano R, Napolitano G et al. Pancreatic duct stents in the prophylaxis of pancreatic damage after endoscopic retrograde cholangiopancreatography: a systematic analysis of benefits and associated risks. Digestion 2007 75 156-163
21. Williams E J., Taylor S, Fairclough P et al. Are we meeting the standards set for endoscopy? Results of a large-scale prospective survey of endoscopic retrograde cholangio-pancreatograph practice. Gut 2007 56 821-829
22. Varadarajulu S, Kilgore M L., Wilcox C M., Eloubeidi M A. Relationship among hospital ERCP volume, length of stay, and technical outcomes. Gastrointest Endosc 2006 64 338-347
23. Allison M C., Ramanaden D N., Fouweather M G., Davis D K., Colin-Jones D G. Provision of ERCP services and training in the United Kingdom. Endoscopy 2000 32 693-699
24. Hilsden R J., Romagnuolo J, May G R. Patterns of use of endoscopic retrograde cholangiopancreatography in a Canadian province. Can J Gastroenterol 2004 18 619-624
25. Colton J, Curran C. Quality indicators, including complications, of ERCP in a community setting: a prospective study. Gastrointest Endosc 2009 70 457-467
26. Rabenstein T, Roggenbuck S, Framke B et al. Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP? Gastrointest Endosc 2002 55 476-483
27. Gottlieb K, Sherman S, Pezzi J, Esber E, Lehman G A. Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes. Am J Gastroenterol 1996 91 1553-1557
28. Testoni P A., Bagnolo F. Pain at 24 hours associated with amylase levels greater than 5 times the upper normal limit as the most reliable indicator of post-ERCP pancreatitis. Gastrointest Endosc 2001 53 33-39
29. Kapetanos D, Kokozidis G, Kinigopoulou P et al. The value of serum amylase and elastase measurements in the prediction of post-ERCP acute pancreatitis. Hepato-Gastroenterol 2007 54 556-560
30. Thomas P R., Sengupta S. Prediction of pancreatitis following endoscopic retrograde cholangiopancreatography by the 4-h post procedure amylase level. J Gastroenterol Hepatol 2001 16 923-926
31. Ito K, Fujita N, Noda Y et al. Relationship between post-ERCP pancreatitis and the change of serum amylase level after the procedure. World J Gastroenterol 2007 13 3855-3860
32. Dai H-F, Wang X-W, Zhao K. Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: a meta-analysis. Hepatobiliary Pancreat Dis Int 2009 8 11-16
33. Elmunzer B, Waljee A, Elta G et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008 57 1262
34. Zheng M-H, Xia H, Chen Y-P. Rectal administration of NSAIDs in the prevention of post-ERCP pancreatitis: a complementary meta-analysis. Gut 2008 57 1632
35. Bang U C., Nojgaard C, Andersen P K., Matzen P. Meta-analysis: Nitroglycerin for prevention of post-ERCP pancreatitis. Aliment Pharmacol Ther 2009 29 1078-1085
36. Shao L M., Chen Q Y., Chen M Y., Cai J T. Nitroglycerin in the prevention of post-ERCP pancreatitis: a meta-analysis. Dig Dis Sci 2010 55 1-7
37. Raty S, Sand J, Pulkkinen M, Matikainen M, Nordback I. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg 2001 5 339-345; discussion 345
38. Andriulli A, Clemente R, Solmi L et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002 56 488-495
39. Andriulli A, Solmi L, Loperfido S et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004 2 713-718
40. Arvanitidis D, Anagnostopoulos G K., Giannopoulos D et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol 2004 19 278-282
41. Benvenutti S, Zancanella L, Piazzi L et al. Prevention of post-ERCP pancreatitis with somatostatin versus gabexate mesylate: A randomized placebo controlled multicenter study. Dig Liv Dis 2006 38 S15
42. Bordas J M., Toledo-Pimentel V, Llach J et al. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc 1998 47 230-234
43. Persson B, Slezak P, Efendic S, Haggmark A. Can somatostatin prevent injection pancreatitis after ERCP? Hepatogastroenterology 1992 39 259-261
44. Poon R T., Yeung C, Liu C L. et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Gut 2003 52 1768-1773
45. Poon R T., Yeung C, Lo C M. et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 1999 49 593-598
46. Saari A, Kivilaakso E, Schroder T. The influence of somatostatin on pancreatic irritation after pancreatography. An experimental and clinical study. Surg Res Comm 1988 2 271-278
47. Arcidiacono R, Gambitta P, Rossi A et al. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy 1994 26 715-718
48. Duvnjak M, Supanc V, Simicevic V N. et al. Use of octreotide-acetate in preventing pancreatitis-like changes following therapeutic endoscopic retrograde cholangiopancreatography. Acta Med Croatica 1999 53 115-118
49. Hardt P D., Kress O, Fadgyas T et al. Octreotide in the prevention of pancreatic damage induced by endoscopic sphincterotomy. Eur J Med Res 2000 5 165-170
50. Li Z S., Pan X, Zhang W J. et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol 2007 102 46-51
51. Manolakopoulos S, Avgerinos A, Vlachogiannakos J et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc 2002 55 470-475
52. Sternlieb J M., Aronchick C A., Retig J N. et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992 87 1561-1566
53. Testoni P A., Bagnolo F, Andriulli A et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001 15 965-972
54. Thomopoulos K C., Pagoni N A., Vagenas K A. et al. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Gastrointest Endosc 2006 64 726-731
55. Cavallini G, Tittobello A, Frulloni L et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy Italian Group. N Engl J Med 1996 335 919-923
56. Manes G, Ardizzone S, Lombardi G et al. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc 2007 65 982-987
57. Xiong G S., Wu S M., Zhang X W., Ge Z Z. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Braz J Med Biol Res 2006 39 85-90
58. Fujishiro H, Adachi K, Imaoka T et al. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol 2006 21 1065-1069
59. Tsujino T, Komatsu Y, Isayama H et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005 3 376-383
60. Ueki T, Otani K, Kawamoto K et al. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial. J Gastroenterol 2007 42 161-167
61. Yoo J W., Ryu J K., Lee S H. et al. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial. Pancreas 2008 37 366-370
62. Bai Y, Gao J, Shi X, Zou D, Li Z. Prophylactic corticosteroids do not prevent post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. Pancreatology 2008 8 504-509
63. Zheng M, Bai J, Yuan B et al. Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. BMC Gastroenterol 2008 8 6
64. Gorelick A, Barnett J, Chey W, Anderson M, Elta G. Botulinum toxin injection after biliary sphincterotomy. Endoscopy 2004 36 170-173
65. Matsushita M, Takakuwa H, Shimeno N et al. Epinephrine sprayed on the papilla for prevention of post-ERCP pancreatitis. J Gastroenterol 2009 44 71-75
66. Schwartz J J., Lew R J., Ahmad N A. et al. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc 2004 59 179-184
67. Prat F, Amaris J, Ducot B et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 2002 56 202-208
68. Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 1993 54 105-111
69. Bai Y, Gao J, Zhang W, Zou D, Li Z. Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis. Aliment Pharmacol Ther 2008 28 557-564
70. Zheng M, Chen Y, Bai J et al. Meta-analysis of prophylactic allopurinol use in post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas 2008 37 247-253
71. Andriulli A, Annese V. Risk of post-endoscopic retrograde cholangiopancreatography pancreatitis and ways to prevent it: old myths, a current need? The case of allopurinol. Clin Gastroenterol Hepatol 2008 6 374-376
72. Katsinelos P, Kountouras J, Paroutoglou G et al. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc 2005 62 105-111
73. Milewski J, Rydzewska G, Degowska M, Kierzkiewicz M, Rydzewski A. N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. World J Gastroenterol 2006 12 3751-3755
74. Lavy A, Karban A, Suissa A et al. Natural beta-carotene for the prevention of post-ERCP pancreatitis. Pancreas 2004 29 e45-e50
75. Barkay O, Niv E, Santo E et al. Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial. Surg Endosc 2008 22 1971-1976
76. Rabenstein T, Fischer B, Wiessner V et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004 59 606-613
77. Deviere J, Le Moine O, Van Laethem J L. et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001 120 498-505
78. Dumot J A., Conwell D L., Zuccaro G Jr et al. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001 96 2098-2102
79. Sherman S, Cheng C L., Costamagna G et al. Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas 2009 38 267-274
80. Sherman S, Cheng C-L, Costamagna G et al. Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas 2009 38 267-274
81. Kapetanos D, Kokozidis G, Christodoulou D et al. A randomized controlled trial of pentoxifylline for the prevention of post-ERCP pancreatitis. Gastrointest Endosc 2007 66 513-518
82. Sherman S, Alazmi W M., Lehman G A. et al. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis. Gastrointest Endosc 2009 69 462-472
83. van Westerloo D J., Rauws E A., Hommes D et al. Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence. Gastrointest Endosc 2008 68 246-254
84. Terruzzi V, Radaelli F, Meucci G, Minoli G. Is the supine position as safe and effective as the prone position for endoscopic retrograde cholangiopancreatography? A prospective randomized study. Endoscopy 2005 37 1211-1214
85. Tringali A, Mutignani M, Milano A, Perri V, Costamagna G. No difference between supine and prone position for ERCP in conscious sedated patients: a prospective randomized study. Endoscopy 2008 40 93-97
86. Vandervoort J, Soetikno R M., Tham T CK et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002 56 652-656
87. Cheon Y K., Cho K B., Watkins J L. et al. Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification. Gastrointest Endosc 2007 65 385-393
88. George S, Kulkarni A A., Stevens G, Forsmark C E., Draganov P. Role of osmolality of contrast media in the development of post-ERCP pancreatitis: a meta-analysis. Dig Dis Sci 2004 49 503-508
89. 2) insufflation during ERCP for the reduction of post-procedure pain: preliminary results of a randomized, double-blind controlled trial. Gastrointest Endosc 2008 67 AB107
90. Maple J T., Keswani R N., Hovis R M. et al. Carbon dioxide insufflation during ERCP for reduction of postprocedure pain: a randomized, double-blind, controlled trial. Gastrointest Endosc 2009 70 278-283
91. Cennamo V, Fuccio L, Zagari R M. et al. Can a wire-guided cannulation technique increase bile duct cannulation rate and prevent post-ERCP pancreatitis?: A meta-analysis of randomized controlled trials. Am J Gastroenterol 2009 104 2343-2350
92. Choudhary A, Puli S, Ibdah J, Bechtold M. Guidewire use for prevention of post ERCP pancreatitis: a meta-analysis of randomized controlled trials. Gastrointest Endosc 2009 69 AB305
93. Madhoun M, Te C, Stoner J, Maple J. Does wire-guided cannulation prevent post-ERCP pancreatitis? A meta-analysis. Gastrointest Endosc 2009 69 AB132
94. Cheung J, Tsoi K K., Quan W-L, Lau J YW, Sung J JY. Guidewire versus conventional contrast cannulation of the common bile duct for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis. Gastrointest Endosc 2009 70 1211-1219
95. Verma D, Kapadia A, Adler D G. Pure versus mixed electrosurgical current for endoscopic biliary sphincterotomy: a meta-analysis of adverse outcomes. Gastrointest Endosc 2007 66 283-290
96. Herreros de Tejada A, Calleja J L., Daz G et al. Double-guidewire technique for difficult bile duct cannulation: a multicenter randomized, controlled trial. Gastrointest Endosc 2009 70 700-709
97. Maeda S, Hayashi H, Hosokawa O et al. Prospective randomized pilot trial of selective biliary cannulation using pancreatic guide-wire placement. Endoscopy 2003 35 721-724
98. Ito K, Fujita N, Noda Y et al. Can pancreatic duct stenting prevent post-ERCP pancreatitis in patients who undergo pancreatic guidewire placement for achieving selective biliary cannulation? A prospective randomized controlled trial. Endoscopy 2008 40 (Suppl 1) A17
99. Nguyen-Tang T, Dumonceau J M. Double-guidewire technique for difficult bile duct cannulation: why not insert a prophylactic pancreatic stent? Gastrointest Endosc 2010 in press
100. Iqbal S, Sharma P, Shah S. Role of double guide wire cannulation during ERCP. Gastrointest Endosc 2008 67 AB158
101. Ito K, Fujita N, Noda Y et al. Pancreatic guidewire placement for achieving selective biliary cannulation during endoscopic retrograde cholangio-pancreatography. World J Gastroenterol 2008 14 5595-5600; discussion 5599
102. Patel S, Torres V, Gross G. The early use of the double-wire technique to facilitate difficult biliary cannulation and its impact on post-ERCP pancreatitis. Gastrointest Endosc 2009 69 AB159
103. Gykeres T, Duhl J, Varsnyi M et al. Double guide wire placement for endoscopic pancreaticobiliary procedures. Endoscopy 2003 35 95-96
104. Cennamo V, Fuccio L, Repici A et al. Timing of precut procedure does not influence success rate and complications of ERCP procedure: a prospective randomized comparative study. Gastrointest Endosc 2009 69 473-479
105. Wang P, Li Z-S, Liu F et al. Risk factors for ERCP-related complications: a prospective multicenter study. Am J Gastroenterol 2009 104 31-40
106. Akaraviputh T, Lohsiriwat V, Swangsri J et al. The learning curve for safety and success of precut sphincterotomy for therapeutic ERCP: a single endoscopists experience. Endoscopy 2008 40 513-516
107. Fukatsu H, Kawamoto H, Harada R et al. Quantitative assessment of technical proficiency in performing needle-knife precut papillotomy. Surg Endosc 2009 23 2066-2072
108. Harewood G C., Baron T H. An assessment of the learning curve for precut biliary sphincterotomy. Am J Gastroenterol 2002 97 1708-1712
109. Manes G, Di Giorgio P, Repici A et al. An analysis of the factors associated with the development of complications in patients undergoing precut sphincterotomy: a prospective, controlled, randomized, multicenter study. Am J Gastroenterol 2009 104 2412-2417
110. de Weerth A, Seitz U, Zhong Y et al. Primary precutting versus conventional over-the-wire sphincterotomy for bile duct access: a prospective randomized study. Endoscopy 2006 38 1235-1240
111. Tang S-J, Haber G B., Kortan P et al. Precut papillotomy versus persistence in difficult biliary cannulation: a prospective randomized trial. Endoscopy 2005 37 58-65
112. Yasuda I, Tomita E, Enya M, Kato T, Moriwaki H. Can endoscopic papillary balloon dilation really preserve sphincter of Oddi function? Gut 2001 49 686-691
113. Baron T H., Harewood G C. Endoscopic balloon dilation of the biliary sphincter compared to endoscopic biliary sphincterotomy for removal of common bile duct stones during ERCP: a metaanalysis of randomized, controlled trials. Am J Gastroenterol 2004 99 1455-1460
114. Weinberg B M., Shindy W, Lo S. Endoscopic balloon sphincter dilation (sphincteroplasty) versus sphincterotomy for common bile duct stones. Cochrane Database Syst Rev 2006 CD004890
115. DiSario J A., Freeman M L., Bjorkman D J. et al. Endoscopic balloon dilation compared with sphincterotomy for extraction of bile duct stones. Gastroenterology 2004 127 1291-1299
116. Attasaranya S, Cheon Y, Vittal H et al. Large-diameter biliary orifice balloon dilation to aid in endoscopic bile duct stone removal: a multicenter series. Gastrointest Endosc 2008 67 1046-1052
117. Ersoz G, Tekesin O, Ozutemiz A O., Gunsar F. Biliary sphincterotomy plus dilation with a large balloon for bile duct stones that are difficult to extract. Gastrointest Endosc 2003 57 156-159
118. Maydeo A, Bhandari S. Balloon sphincteroplasty for removing difficult bile duct stones. Endoscopy 2007 39 958-961
119. Minami A, Hirose S, Nomoto T, Hayakawa S. Small sphincterotomy combined with papillary dilation with large balloon permits retrieval of large stones without mechanical lithotripsy. World J Gastroenterol 2007 13 2179-2182
120. Misra S P., Dwivedi M. Large-diameter balloon dilation after endoscopic sphincterotomy for removal of difficult bile duct stones. Endoscopy 2008 40 209-213
121. Heo J H., Kang D H., Jung H J. et al. Endoscopic sphincterotomy plus large-balloon dilation versus endoscopic sphincterotomy for removal of bile-duct stones. Gastrointest Endosc 2007 66 720-726; quiz 768, 771
122. Kawamoto M, Geenen J, Omari T et al. Sleeve sphincter of Oddi (SO) manometry: a new method for characterizing the motility of the sphincter of Oddi. J Hepatobiliary Pancreat Surg 2008 15 391-396
123. Frenz M B., Wehrmann T. Solid state biliary manometry catheter: impact on diagnosis and post-study pancreatitis. Curr Gastroenterol Rep 2007 9 171-174
124. Craig A G., Omari T, Lingenfelser T et al. Development of a sleeve sensor for measurement of sphincter of Oddi motility. Endoscopy 2001 33 651-657
125. Sherman S, Troiano F P., Hawes R H., Lehman G A. Sphincter of Oddi manometry: decreased risk of clinical pancreatitis with use of a modified aspirating catheter. Gastrointest Endosc 1990 36 462-466
126. Draganov P, Kowalczyk L, Forsmark C. Prospective trial comparing solid-state catheter and water-perfusion triple-lumen catheter for sphincter of Oddi manometry done at the time of ERCP. Gastrointest Endosc 2009 70 92-95
127. Wehrmann T, Stergiou N, Schmitt T, Dietrich C F., Seifert H. Reduced risk for pancreatitis after endoscopic microtransducer manometry of the sphincter of Oddi: a randomized comparison with the perfusion manometry technique. Endoscopy 2003 35 472-477 (Pubitemid 36705637)
128. Sherman S, Hawes R H., Troiano F P., Lehman G A. Pancreatitis following bile duct sphincter of Oddi manometry: utility of the aspirating catheter. Gastrointest Endosc 1992 38 347-350
129. Singh P, Das A, Isenberg G et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 2004 60 544-550
130. Sofuni A, Maguchi H, Itoi T et al. Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. Clin Gastroenterol Hepatol 2007 5 1339-1346
131. Chahal P, Tarnasky P, Petersen B et al. Short 5Fr vs long 3Fr pancreatic stents in patients at high risk for post- endoscopic cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2009 7 834-839
132. Fehmi S MA, Schoenfeld P S., Scheiman J M. et al. 5 Fr prophylactic pancreatic stents are easier to place and require fewer guide wires than 3 Fr stents. Gastrointest Endosc 2008 67 AB328-AB329
133. Smith M T., Sherman S, Ikenberry S O., Hawes R H., Lehman G A. Alterations in pancreatic ductal morphology following polyethylene pancreatic stent therapy. Gastrointest Endosc 1996 44 268-275
134. Das A, Singh P, Sivak M V., Chak A. Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis. Gastrointest Endosc 2007 65 960-968
135. Freeman M L., Overby C, Qi D. Pancreatic stent insertion: consequences of failure and results of a modified technique to maximize success. Gastrointest Endosc 2004 59 8-14
136. Brackbill S, Young S, Schoenfeld P, Elta G. A survey of physician practices on prophylactic pancreatic stents. Gastrointest Endosc 2006 64 45-52
137. Dumonceau J M., Rigaux J, Kahaleh M et al. Prophylaxis of post-ERCP pancreatitis: a practice survey. Gastrointest Endosc 2010 71 934-939